Strategic Funding and Joint-Development
Business Model
SFJ Pharmaceuticals Group can provide incremental funding and/or resources to drug development programs to reduce P&L pressure and maximize portfolio potential with no risk to the Pharma or Biotech partner. Reimbursement is completely dependent on regulatory approval.
  1. SFJ ASSUMES 100% OF THE DEVELOPMENT & APPROVAL RISKS
    For example, if SFJ invests $100 million in a Phase III clinical study and the drug is NOT approved then SFJ loses its investment. However, if the drug is approved then the Pharma Partner pays SFJ milestone payments over the next 8 to10 years following approval.
  2. SFJ CAN FUND AND/OR EXECUTE STUDIES AT A GLOBAL, REGIONAL, OR COUNTRY LEVEL INCLUDING CHINA AND JAPAN
    SFJ recognizes that each of our current and future Pharma Partners have distinct needs and requirements. As such, SFJ first listens to our Pharma Partners to thoroughly understand their specific funding, legal and operational needs and then jointly develops a co-development framework that is specifically tailored to the Pharma Partner’s needs.